Payment overview · 2025
General Payments
$313.51
15 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Davis Holmes, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · HARRIMAN, TN · NPI 1760544621
Verified facts
What the public records show
CMS Open Payments records show Michael Davis Holmes, FNP-BC received $313.51 in general payments during 2025 across 15 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $71.71 | 22.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.40 | 20.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.05 | 16.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.67 | 11.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.42 | 7.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.52 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.83 | 5.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.45 | 4.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $13.46 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $313.51 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $71.71 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.40 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
150 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 426 | 141 |
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 142 |
| Gabapentin | Gabapentin | 391 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 281 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 95 |
| Metformin Hcl | Metformin Hcl | 264 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 237 | 96 |
| Omeprazole | Omeprazole | 227 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 80 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 187 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 61 |
| Prednisone | Prednisone | 173 | 121 |
| Losartan Potassium | Losartan Potassium | 165 | 63 |
| Pregabalin | Pregabalin | 165 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 164 | 26 |
| Trazodone Hcl | Trazodone Hcl | 157 | 63 |
| Ozempic | Semaglutide | 150 | 42 |
| Sertraline Hcl | Sertraline Hcl | 149 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 144 | 66 |
| Furosemide | Furosemide | 138 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 63 |
| Alprazolam | Alprazolam | 127 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 49 |
| Potassium Chloride | Potassium Chloride | 109 | 48 |
| Montelukast Sodium | Montelukast Sodium | 108 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 54 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 81 |
| Azithromycin | Azithromycin | 100 | 79 |
| Ondansetron Odt | Ondansetron | 96 | 37 |
| Buspirone Hcl | Buspirone Hcl | 90 | 30 |
| Glimepiride | Glimepiride | 90 | 25 |
| Famotidine | Famotidine | 89 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 29 |
| Meloxicam | Meloxicam | 88 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 23 |
| Simvastatin | Simvastatin | 86 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 32 |
| Eliquis | Apixaban | 85 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 25 |
| Tramadol Hcl | Tramadol Hcl | 83 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 24 |
| Jardiance | Empagliflozin | 77 | 17 |
| Mounjaro | Tirzepatide | 77 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 32 |
| Carvedilol | Carvedilol | 75 | 29 |
| Lorazepam | Lorazepam | 73 | 14 |
| Propranolol Hcl | Propranolol Hcl | 73 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 73 | 14 |
| Mirtazapine | Mirtazapine | 72 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 67 | 35 |
| Atenolol | Atenolol | 63 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 28 |
| Diazepam | Diazepam | 61 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 53 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 24 |
| Ibuprofen | Ibuprofen | 56 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 25 |
| Allopurinol | Allopurinol | 53 | 16 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 22 |
| Linzess | Linaclotide | 48 | 18 |
| Baclofen | Baclofen | 46 | 17 |
| Promethazine Hcl | Promethazine Hcl | 46 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 17 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 13 |
| Verapamil Er | Verapamil Hcl | 43 | 14 |
| Cefdinir | Cefdinir | 42 | 38 |
| Celecoxib | Celecoxib | 42 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | 19 |
| Alendronate Sodium | Alendronate Sodium | 40 | 13 |
| Doxepin Hcl | Doxepin Hcl | 40 | 21 |
| Vraylar | Cariprazine Hcl | 40 | suppressed |
| Estradiol | Estradiol | 39 | 16 |
| Fluconazole | Fluconazole | 39 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 16 |
| Benazepril Hcl | Benazepril Hcl | 36 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 14 |
| Levetiracetam | Levetiracetam | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 12 |
| Ezetimibe | Ezetimibe | 32 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 14 |
| Sucralfate | Sucralfate | 30 | 12 |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 23 |
| Ramipril | Ramipril | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | 11 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Naproxen | Naproxen | 20 | 13 |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 14 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $313.51 · 15 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, CAPLYTA, FANAPT, GEMTESA, HETLIOZ, SPRAVATO, VOQUEZNA, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error